Stereotactic Radiation Therapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC)

Official Title

Stereotactic Radiation Therapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC): A Randomized Phase II Trial

Summary:

A multicentre randomized phase II trial of stereotactic body radiation therapy for oligo-progressive non-small cell lung cancer. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiation therapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).

Trial Description

Primary Outcome:

• Progression-Free Survival

• Overall Survival
• Quality of Life
• Toxicity
• Lesional Control Rate
• Total Time on Chemotherapy
• Duration of current systemic agent treatment after SABR
• Location of sites of further progression after SABR

View this trial on ClinicalTrials.gov